GSK (GSK -2.7%) withdraws a supplemental New Drug Application to the FDA to use its Tykerb drug...

|By:, SA News Editor

GSK (GSK -2.7%) withdraws a supplemental New Drug Application to the FDA to use its Tykerb drug in combination with Genentech's Herceptin for the treatment of a certain type of breast cancer in patients who have already received Herceptin. "Our discussions with FDA highlighted questions that could not be addressed with the data currently available," GSK says.